VITA 34 International AG restructures management team after returning to the black

VITA 34 International AG / Change of Personnel


Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.


* Dr. Eberhard Lampeter remains CEO of the company
* Streamlined structure aimed at further increasing profitability 
* Jörg Ulbrich takes charge of Finance at VITA 34 International
* Marketing and Sales to be realigned

Leipzig, October 19, 2009. VITA 34 International AG (ISIN DE000A0BL849),
the parent company of the leading umbilical cord blood bank in the G/S/A
region VITA 34, has decided to restructure its management team after
successfully returning to the black. This move is to lay the foundations
for further increasing profitability in the coming years. Dr. Eberhard
Lampeter, founder and CEO of VITA 34 AG, will continue to head the company.

Finance will be headed by Jörg Ulbrich in the future. Mr. Ulbrich was in
charge of Administration at VITA 34 up to now and therefore has an in-depth
insight into the company. The previous CFO, Peter Boehnert, has requested
to leave the company from October 31, 2009. He is now looking for a new
challenge elsewhere. He leaves on good terms after successfully
implementing cost reduction measures which were launched in mid 2008. The
VITA 34 International AG Supervisory Board agreed to his request and would
like to thank Mr. Boehnert for his outstanding work. It would also like to
wish him all the best for his future career.

Oliver Papavlassopoulos has also announced that he will be stepping down
from his position as Chief Marketing Officer on October 31, 2009. He is
planning to work on a self-employed basis in the future. In the last few
years, he has been highly successful in paving the way for VITA 34's
internationalization. The Supervisory Board would like to thank Mr.
Papavlassopoulos for his successful work and wishes him all the best for
his future plans. The new appointments in this area of the company
represent a careful realignment of Marketing and Sales, and these measures
are to create a better benefit-cost ratio. The overall aim is to support
further earnings increases in the coming years.

After its highly successful development in the first three quarters of
2009, VITA 34 is confirming its forecast for the full year. The leading
private umbilical cord blood bank in the G/S/A region is expecting to reach
or even beat its stated objective of at least breaking even at EBIT level
this year. Further increases in all earnings figures are expected for 2010.

Axel Mühlhaus
Dr. Sönke Knop
edicto GmbH
Zeißelstraße 19
D-60318 Frankfurt
Tel.:+49 (069) 90550550
Fax: +49 (069) 90550577

19.10.2009  financial News transmitted by DGAP

Language:     English
Company:      VITA 34 International AG
              Deutscher Platz 5a
              04103 Leipzig
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, München, Hamburg, Stuttgart
End of News                                     DGAP News-Service